Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERNNASDAQ:ICPTNASDAQ:IMGNNASDAQ:INVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.28+8.5%$1.48$1.17▼$5.34$815.26M0.7611.52 million shs12.54 million shsICPTIntercept Pharmaceuticals$19.00$18.88$8.82▼$21.86$794.77M0.881.36 million shsN/AIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shs40 shsINVAInnoviva$18.61+0.3%$17.92$15.20▼$21.28$1.17B0.35632,164 shs546,033 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron+8.02%-9.86%-7.25%-54.12%-66.32%ICPTIntercept Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IMGNImmunoGen0.00%0.00%0.00%0.00%0.00%INVAInnoviva+0.27%-0.69%+6.22%+3.05%+19.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron4.0841 of 5 stars4.41.00.01.32.83.30.6ICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIMGNImmunoGenN/AN/AN/AN/AN/AN/AN/AN/AINVAInnoviva4.2436 of 5 stars3.50.00.04.22.82.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.78Moderate Buy$5.06295.51% UpsideICPTIntercept Pharmaceuticals 0.00N/AN/AN/AIMGNImmunoGen 0.00N/AN/AN/AINVAInnoviva 3.00Buy$55.00195.54% UpsideCurrent Analyst Ratings BreakdownLatest INVA, IMGN, GERN, and ICPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$4.00 ➝ $1.503/12/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.002/27/2025GERNGeronBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$9.00 ➝ $4.002/27/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $4.002/27/2025GERNGeronStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.002/27/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.002/27/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.50 ➝ $2.002/26/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/18/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.50(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$116.29M7.01N/AN/A$0.46 per share2.78ICPTIntercept Pharmaceuticals$285.71M2.78N/AN/A$1.72 per share11.05IMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99INVAInnoviva$369.84M3.15$3.60 per share5.17$10.66 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$184.13M-$0.21N/AN/AN/A-682.48%-67.53%-45.46%N/AICPTIntercept Pharmaceuticals$221.82M-$1.48N/A9.84N/A-19.39%-77.48%-11.99%N/AIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AINVAInnoviva$179.72M-$1.0126.9712.01N/A18.31%20.84%11.38%5/14/2025 (Estimated)Latest INVA, IMGN, GERN, and ICPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025GERNGeron-$0.04-$0.03+$0.01-$0.03$49.88 million$39.60 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million2/26/2025Q4 2024GERNGeron-$0.04-$0.04N/A-$0.04$45.29 million$47.54 million2/26/2025Q4 2024INVAInnovivaN/A$0.57N/A$0.26N/A$91.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AICPTIntercept PharmaceuticalsN/AN/AN/AN/AN/AIMGNImmunoGenN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.042.892.74ICPTIntercept Pharmaceuticals3.124.222.52IMGNImmunoGen0.135.705.65INVAInnoviva0.381.791.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%ICPTIntercept Pharmaceuticals83.81%IMGNImmunoGen90.50%INVAInnoviva99.12%Insider OwnershipCompanyInsider OwnershipGERNGeron7.42%ICPTIntercept Pharmaceuticals6.20%IMGNImmunoGen5.07%INVAInnoviva2.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron70636.92 million585.76 millionOptionableICPTIntercept Pharmaceuticals34141.83 million39.19 millionOptionableIMGNImmunoGen277266.26 million252.76 millionOptionableINVAInnoviva10062.68 million61.54 millionOptionableINVA, IMGN, GERN, and ICPT HeadlinesRecent News About These CompaniesJane Street Group LLC Purchases 194,270 Shares of Innoviva, Inc. (NASDAQ:INVA)May 12 at 4:06 AM | marketbeat.comBridgeway Capital Management LLC Has $3.23 Million Stake in Innoviva, Inc. (NASDAQ:INVA)May 11 at 6:00 AM | marketbeat.com4 Undervalued Pharmaceuticals Stocks for Friday, May 09May 9, 2025 | aaii.comTheravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | ...May 9, 2025 | gurufocus.comTheravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...May 9, 2025 | gurufocus.comInnoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are SellingMay 8, 2025 | msn.comSchonfeld Strategic Advisors LLC Purchases 14,957 Shares of Innoviva, Inc. (NASDAQ:INVA)May 8, 2025 | marketbeat.comInnoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company ProgressMay 7, 2025 | businesswire.comSusquehanna Fundamental Investments LLC Acquires New Stake in Innoviva, Inc. (NASDAQ:INVA)May 7, 2025 | marketbeat.comFreestone Grove Partners LP Invests $674,000 in Innoviva, Inc. (NASDAQ:INVA)May 6, 2025 | marketbeat.comInnoviva (NASDAQ:INVA) Upgraded at StockNews.comMay 2, 2025 | marketbeat.comInnoviva, Inc. (NASDAQ:INVA) Shares Acquired by Dimensional Fund Advisors LPMay 2, 2025 | marketbeat.comHsbc Holdings PLC Invests $5.44 Million in Innoviva, Inc. (NASDAQ:INVA)May 1, 2025 | marketbeat.comRep. George Whitesides Unloads Shares of Innoviva, Inc. (NASDAQ:INVA)April 28, 2025 | marketbeat.comRep. George Whitesides Sells Off Shares of Innoviva, Inc. (NASDAQ:INVA)April 28, 2025 | marketbeat.comMarshall Wace LLP Buys 178,583 Shares of Innoviva, Inc. (NASDAQ:INVA)April 26, 2025 | marketbeat.comStockNews.com Downgrades Innoviva (NASDAQ:INVA) to HoldApril 23, 2025 | marketbeat.comInvesco Ltd. Has $18.25 Million Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)April 21, 2025 | marketbeat.comLSV Asset Management Has $696,000 Position in Innoviva, Inc. (NASDAQ:INVA)April 17, 2025 | marketbeat.comInnoviva (NASDAQ:INVA) Raised to Buy at StockNews.comApril 16, 2025 | marketbeat.comRussell Investments Group Ltd. Decreases Stock Position in Innoviva, Inc. (NASDAQ:INVA)April 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINVA, IMGN, GERN, and ICPT Company DescriptionsGeron NASDAQ:GERN$1.28 +0.10 (+8.47%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$1.24 -0.04 (-3.13%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Intercept Pharmaceuticals NASDAQ:ICPTIntercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..ImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Innoviva NASDAQ:INVA$18.61 +0.05 (+0.27%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$18.43 -0.18 (-0.97%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
